OUTLOOK THERAPEUTICS, INC. Operating Expenses
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Operating Expenses of $19.56 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2024-08-14
- OUTLOOK THERAPEUTICS, INC. operating expenses for the quarter ending 2024-06-30 was $19.56M, a 7.83% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. operating expenses for the quarter ending 2024-03-31 was $18.94M, a 176.98% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. operating expenses for the quarter ending 2023-06-30 was $18.14M.
- OUTLOOK THERAPEUTICS, INC. operating expenses for the quarter ending 2023-03-31 was $6.84M.
- OUTLOOK THERAPEUTICS, INC. operating expenses for fiscal 2021 was $51.73M, a 40.41% increase from fiscal 2020.
- OUTLOOK THERAPEUTICS, INC. operating expenses for fiscal 2020 was $36.84M, a 17.11% decline from fiscal 2019.
- OUTLOOK THERAPEUTICS, INC. operating expenses for fiscal 2019 was $44.45M, a 35.79% increase from fiscal 2018.
- OUTLOOK THERAPEUTICS, INC. operating expenses for fiscal 2018 was $32.73M, a 17.53% decline from fiscal 2017.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | $19.56M 10-Q · filed 2024-08-14 | $38.50M derived: sum of 2 quarters · filed 2024-08-14 | $48.83M 10-Q · filed 2024-08-14 | |||||
| 2024-03-31 | $18.94M 10-Q · filed 2024-05-15 | $29.26M 10-Q · filed 2024-05-15 | ||||||
| 2023-06-30 | $18.14M 10-Q · filed 2024-08-14 | $24.98M derived: sum of 2 quarters · filed 2024-08-14 | $40.67M 10-Q · filed 2024-08-14 | |||||
| 2023-03-31 | $6.84M 10-Q · filed 2024-05-15 | $22.53M 10-Q · filed 2024-05-15 | ||||||
| 2021-09-30 | $13.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-23 | $24.91M derived: sum of 2 quarters · filed 2021-12-23 | $37.54M derived: sum of 3 quarters · filed 2021-12-23 | $51.73M 10-K · filed 2021-12-23 | ||||
| 2021-06-30 | $11.47M 10-Q · filed 2021-08-13 | $24.10M derived: sum of 2 quarters · filed 2021-08-13 | $38.29M 10-Q · filed 2021-08-13 | $48.30M derived: sum of 4 quarters · filed 2021-12-23 | ||||
| 2021-03-31 | $12.63M 10-Q · filed 2021-05-14 | $26.82M 10-Q · filed 2021-05-14 | $36.83M derived: sum of 3 quarters · filed 2021-12-23 | $48.71M derived: sum of 4 quarters · filed 2021-12-23 | ||||
| 2020-12-31 | $14.19M 10-Q · filed 2021-02-16 | $24.20M derived: sum of 2 quarters · filed 2021-12-23 | $36.08M derived: sum of 3 quarters · filed 2021-12-23 | $42.85M derived: sum of 4 quarters · filed 2021-12-23 | ||||
| 2020-09-30 | $10.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-23 | $21.89M derived: sum of 2 quarters · filed 2021-12-23 | $28.66M derived: sum of 3 quarters · filed 2021-12-23 | $36.84M 10-K · filed 2021-12-23 | ||||
| 2020-06-30 | $11.88M 10-Q · filed 2021-08-13 | $18.64M derived: sum of 2 quarters · filed 2021-08-13 | $26.83M 10-Q · filed 2021-08-13 | $45.37M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $6.76M 10-Q · filed 2021-05-14 | $14.95M 10-Q · filed 2021-05-14 | $33.49M derived: sum of 3 quarters · filed 2021-05-14 | $39.72M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | $8.18M 10-Q · filed 2021-02-16 | $26.73M derived: sum of 2 quarters · filed 2021-02-16 | $32.96M derived: sum of 3 quarters · filed 2021-02-16 | $41.30M derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2019-09-30 | $18.55M derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-23 | $24.77M derived: sum of 2 quarters · filed 2020-12-23 | $33.12M derived: sum of 3 quarters · filed 2020-12-23 | $44.45M 10-K · filed 2020-12-23 | ||||
| 2019-06-30 | $6.23M 10-Q · filed 2020-08-14 | $14.57M derived: sum of 2 quarters · filed 2020-08-14 | $25.90M 10-Q · filed 2020-08-14 | $39.09M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | $8.35M 10-Q · filed 2020-05-15 | $19.67M 10-Q · filed 2020-05-15 | $32.86M derived: sum of 3 quarters · filed 2020-05-15 | $40.85M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $11.32M 10-Q · filed 2020-02-14 | $24.51M derived: sum of 2 quarters · filed 2020-02-14 | $32.50M derived: sum of 3 quarters · filed 2020-02-14 | $40.11M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-09-30 | $13.19M derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-19 | $21.18M derived: sum of 2 quarters · filed 2019-12-19 | $28.78M derived: sum of 3 quarters · filed 2019-12-19 | $32.73M 10-K · filed 2019-12-19 | ||||
| 2018-06-30 | $7.99M 10-Q · filed 2019-08-14 | $15.59M derived: sum of 2 quarters · filed 2019-08-14 | $19.55M 10-Q · filed 2019-08-14 | $25.36M derived: sum of 4 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | $7.60M 10-Q · filed 2019-05-15 | $11.55M 10-Q · filed 2019-05-15 | $17.37M derived: sum of 3 quarters · filed 2019-05-15 | $25.01M derived: sum of 4 quarters · filed 2019-05-15 | ||||
| 2017-12-31 | $3.95M 10-Q · filed 2019-02-14 | $9.76M derived: sum of 2 quarters · filed 2019-02-14 | $17.40M derived: sum of 3 quarters · filed 2019-02-14 | $25.55M derived: sum of 4 quarters · filed 2019-02-14 | ||||
| 2017-09-30 | $5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-18 | $13.45M derived: sum of 2 quarters · filed 2018-12-18 | $21.59M derived: sum of 3 quarters · filed 2018-12-18 | $39.69M 10-K · filed 2018-12-18 | ||||
| 2017-06-30 | $7.64M 10-Q · filed 2018-08-14 | $7.74M 10-Q · filed 2017-08-14 | $15.78M derived: sum of 2 quarters · filed 2018-08-14 | $33.88M 10-Q · filed 2018-08-14 | $34.19M 10-Q · filed 2017-08-14 | $44.33M derived: sum of 4 quarters · filed 2018-08-14 | ||
| 2017-03-31 | $8.14M 10-Q · filed 2018-05-15 | $8.24M 10-Q · filed 2017-05-15 | $26.24M 10-Q · filed 2018-05-15 | $26.45M 10-Q · filed 2017-05-15 | $36.69M derived: sum of 3 quarters · filed 2018-05-15 | $59.21M derived: sum of 4 quarters · filed 2018-05-15 | ||
| 2016-12-31 | $18.10M 10-Q · filed 2018-02-14 | $18.20M 10-Q · filed 2017-02-14 | $28.55M derived: sum of 2 quarters · filed 2018-02-14 | $51.07M derived: sum of 3 quarters · filed 2018-02-14 | $55.02M derived: sum of 4 quarters · filed 2018-02-14 | |||
| 2016-09-30 | $10.45M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-29 | $32.97M derived: sum of 2 quarters · filed 2017-12-29 | $36.92M derived: sum of 3 quarters · filed 2017-12-29 | $54.33M 10-K · filed 2017-12-29 | $54.74M 10-K · filed 2016-12-29 | |||
| 2016-06-30 | $22.52M 10-Q · filed 2017-08-14 | $26.47M derived: sum of 2 quarters · filed 2017-08-14 | $43.88M 10-Q · filed 2017-08-14 | $61.75M derived: sum of 4 quarters · filed 2017-08-14 | ||||
| 2016-03-31 | $3.95M 10-Q · filed 2017-05-15 | $21.36M 10-Q · filed 2017-05-15 | $39.22M derived: sum of 3 quarters · filed 2017-05-15 | $51.56M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | $17.41M 10-Q · filed 2017-02-14 | $35.27M derived: sum of 2 quarters · filed 2017-02-14 | $47.62M derived: sum of 3 quarters · filed 2017-02-14 | $62.11M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-09-30 | $17.87M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-29 | $30.21M derived: sum of 2 quarters · filed 2016-12-29 | $44.70M derived: sum of 3 quarters · filed 2016-12-29 | $51.78M 10-K · filed 2016-12-29 | ||||
| 2015-06-30 | $12.34M 10-Q · filed 2016-08-15 | $26.84M derived: sum of 2 quarters · filed 2016-08-15 | $33.92M 10-Q · filed 2016-08-15 | |||||
| 2015-03-31 | $14.50M 10-Q · filed 2016-06-27 | $21.57M 10-Q · filed 2016-06-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |